BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Official Title

A Phase 1b Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours


BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.

Trial Description

Primary Outcome:

  • Incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0
  • Incidence of serious adverse events (SAE) and suspected unexpected serious adverse reactions;
  • Incidence of dose-limiting toxicities (DLT)
  • Incidence of clinically significant changes or abnormalities from Physical Examinations, ECGs, Vital Signs, Laboratory Results (chemistry, hematology, coagulation, urinalysis), Eastern Cooperative Oncology Group (ECOG) performance status
Secondary Outcome:
  • Progression Free Survival (PFS); Overall Response Rate (ORR); Overall Survival (OS)
  • Standard PK parameters including Cmin
  • Baseline GRP78 biomarker levels (Counts/mL)
  • Changes in GRP78 biomarker levels during treatment (Counts/mL)
  • Standard PK parameters including Cmax
  • Standard PK parameters including TSS
  • Standard PK parameters including CSS
  • Standard PK parameters including Vdss

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society